Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Andy zulfiqqar"'
Publikováno v:
Turkish Journal of Nephrology, Vol 33, Iss 1, Pp 113-115 (2024)
Externí odkaz:
https://doaj.org/article/d8a3b2ddff644f70af0b5eba106f53ea
Autor:
Tanaya Ghinorawa, Gilang samudera, Indrawarman Soeroharjo, Ahmad Zulfan Hendri, Andy zulfiqqar
Publikováno v:
Jurnal Urologi Indonesia, Vol 30, Iss 2 (2023)
Objective: This study aims to evaluate the association of the preoperative Neutrophil-lymphocyte ratio (NLR) and postoperative creatinine levels after kidney transplantation, which is a predictor factor for determining early postoperative transplanta
Externí odkaz:
https://doaj.org/article/ef6060b560fb482098b7631abe0c4b9d
Autor:
Indrawarman Soerohardjo, Andy Zulfiqqar, Irianiwati Widodo, Didik Setyo Heriyanto, Sumadi Lukman Anwar
Publikováno v:
Turkish Journal of Urology, Vol 48, Iss 2, Pp 112-117 (2022)
Externí odkaz:
https://doaj.org/article/4001d9bb9c454c0ba796db7335b3da78
Publikováno v:
Jurnal Urologi Indonesia, Vol 30, Iss 1 (2023)
Objective: This study aimed to evaluate medical resident and clerkship preferences for a variety of available Smart e-Learning options to better cope with this global pandemic. Material & Methods: This cross-sectional study using a web-based national
Externí odkaz:
https://doaj.org/article/3bacd9e93c5a49b8be4f8685fdc393a9
Autor:
Andy Zulfiqqar, Franky Renato Anthonius, Prasetyo Amanda Cyko, Pandu Ishaq Nandana, Prahara Yuri, Sakti R Brodjonegoro
Publikováno v:
Jurnal Urologi Indonesia, Vol 28, Iss 1, Pp 14-18 (2021)
Objective: To determine Type-2 diabetic patients and its characteristics to determined risk of Erectile dysfunction (ED) and the role of EHS score as more practical tools to screening ED among T2DM patients. Material & Methods: The cross-sectional ob
Externí odkaz:
https://doaj.org/article/2031f1c87bdb4767ad6e1b91dcef52e9
Autor:
Prahara Yuri, Katsumi Shigemura, Koichi Kitagawa, Exsa Hadibrata, Muhammad Risan, Andy Zulfiqqar, Indrawarman Soeroharjo, Ahmad Z. Hendri, Raden Danarto, Aya Ishii, Saya Yamasaki, Yongmin Yan, Didik S. Heriyanto, Masato Fujisawa
Publikováno v:
Prostate International, Vol 8, Iss 2, Pp 62-69 (2020)
Background: Tumor-associated macrophages (TAMs) and microvessel density (MVD) play an essential role for tumor progression in prostate cancer (PCa). In this study, we evaluated the association between TAMs, the infiltration with tumor angiogenesis an
Externí odkaz:
https://doaj.org/article/7ed3ae6fa522406ca7f5de366b8bb0db
Publikováno v:
Jurnal Urologi Indonesia, Vol 29, Iss 1 (2022)
Objective: This study aims to compare 4 years of experience of IC and TUUC in the same period and among similar experienced surgeons. Material & Methods: Between January 2016 and August 2019, 44 radical cystectomies were performed, but 4 patients wer
Externí odkaz:
https://doaj.org/article/9cbd6917903b436bbc7032a8f76b643d
Autor:
Andy Zulfiqqar, Indrawarman Soeroharjo
Publikováno v:
Jurnal Urologi Indonesia, Vol 27, Iss 2 (2020)
Objective: The aim of this article was to reports our experiences PCNL on ADPKD patients. Case(s) Presentation: We report the case of a 38-year-old male with autosomal dominant polycystic kidney disease associated with bilateral staghorn diseases. We
Externí odkaz:
https://doaj.org/article/55405763d0764dd2a16e4256d850128a
Autor:
Andy Zulfiqqar, Didik Setyo Heriyanto, Nickanor Kaladius Reumy Wonatorey, Sakti Ronggowardhana Brodjonegoro, Tanaya Ghinorawa
Publikováno v:
Medical Journal of Indonesia, Vol 1, Iss 1 (2021)
BACKGROUND Glucose transporters (GLUTs) and oxidant metabolism are associated with the mechanism of infertility. This study evaluated the impact of hyperglycemia on glucose and oxidant metabolisms of Sertoli cells (SCs). METHODS This study was an ani
Autor:
Indrawarman Soerohardjo, Sumadi Lukman Anwar, Didik Setyo Heriyanto, Irianiwati Widodo, Andy Zulfiqqar
Publikováno v:
Annals of Medicine and Surgery. 60:549-554
Introduction Androgen deprivation therapy (ADT) has remained the first line strategy for treatment of advanced prostate cancers. Despite the profound efficacy of ADT in preventing clinical remission, 30–50% of advanced prostate cancer will develop